303

APPENDICES

Study of strategies of top 30 Indian pharmaceutical companies (by domestic turnover) to succeed globally

304

Questionnaire

1. is opting for off patented drugs

a. Already off patented Yes No

b. Going to be off patented Yes No

c. Off patented drugs turnover from the

total business turnover is

< 25%

50-75%

25-50%

> 75 %

2. is having strategy to go for process patent of block buster drugs

a. To challenge the Innovator’s

Process Patent

Yes No

b. Is there any work going on Yes No

c. If yes, in which therapeutic group Yes No

d. Any timeframe Yes No

3. is building R & D infrastructure

a. To make Generic process most cost effective Yes No

b. Exploring Yes No

c. Looking for Contract Research Yes No

d. Gone for Research Collaboration Yes No

e. Made it a profit center Yes No

f. No. of scientists working < 100 100-200

200-300 >300

Study of strategies of top 30 Indian pharmaceutical companies (by domestic turnover) to succeed globally

305

4. is creating facilities for API & dosage form to meet Regulatory

requirement of different countries like USFDA, MHRA, MCA, and TGA etc.

in order to supply to respective countries.

a. For API Yes No

b. For Dosage form Yes No

c. Regulatory market turnover

i. Presently _________ ________

ii. Expected by year 2010 _________ ________

5. is building, buying & collaborating with Pharma companies of

developed world (MNC’s) in order to make dosage form in the developed

countries to have better acceptability of market.

a. Tie up with MNC’s for contract

Manufacturing of Dosage form Yes No

b. Collaboration with no. of MNC’s < 2 3 – 5

6 - 10 > 10

c. Turnover from collaboration < 100 cr 100-200cr

200 –300 cr > 300 cr

6. ‘s investment in R & D is to be brought to minimum 10 - 15% of

the total sales value to focus on basic research in order to invent new

blockbuster drugs.

a. Business focus on generic

Market

Yes No

b. Turnover from generic market < 100 cr 100-200cr

200 –300 cr > 300 cr

c. Investment in R & D to the sale

i. Presently < 2% 2 – 5 %

Study of strategies of top 30 Indian pharmaceutical companies (by domestic turnover) to succeed globally

306

6 – 10 % > 10 %

d. Any work on drug discovery Yes No

7. needs to focus domestic market & strike a balance between domestic

& international business

a. Sales value from domestic

Market

___________________

b. Sales value from international market

___________________

c. Focus therapeutic groups ___________________

d. New launches in domestic market ___________________

e. Market milestone / strategy initiation for

i. Domestic market ___________________

ii. International market

8. needs to target niche market or become super specialist in their

strength therapeutic group

a. Which is your niche product ___________________

b. Which is your niche market ___________________

c. Super specialist in which

Therapeutic group ___________________

d. Turnover from Niche / Total sales in percentage.

___________________

Study of strategies of top 30 Indian pharmaceutical companies (by domestic turnover) to succeed globally

307

9. to adopt following strategies

a. Collaborate with MNC’s Yes No

b. Look for Contract Research Yes No

c. Opt for joint venture Yes No

d. Focus on clinical research Yes No

e. Look for alternative medicine Yes No

f. Work on drug discovery Yes No

………….